- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01599702
Iron Isomaltoside 1000 (Monofer®) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease (IBD-02)
April 28, 2015 updated by: Pharmacosmos A/S
A Prospective, Non-controlled, Safety Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease (PROMISE)
The study is a prospective, non-controlled, open-label multi-centre pilot safety study of iron isomaltoside 1000 (Monofer®) administered to subjects with anaemia and Inflammatory Bowel Disease (IBD).
Based upon haemoglobin (Hb) level, the subjects are divided into two treatment groups, A and B. Depending on the body weight, subjects in Treatment Group A will receive a total dose of 1,500 mg or 2,000 mg IV iron isomaltoside 1000 as a single infusion, whereas subjects in Treatment Group B will receive a total dose of 2,500 mg or 3,000 mg IV iron isomaltoside 1000 divided into two administrations.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Subjects with a diagnosis of IBD (Crohn's disease or ulcerative colitis) and IDA ( Iron Deficiency Anaemia) with or without concomi-tant inflammation will be enrolled to receive a high dose of IV iron isomaltoside 1000.
Study Type
Interventional
Enrollment (Actual)
21
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hoelbaek, Denmark
- Pharmacosmos A/S
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects with age ≥ 18 years
- Subjects diagnosed with IBD either in remission or active
- Hb < 12 g/dL for women and Hb < 13 g/dL for men
- Subjects with a CRP above upper limit of normality must have a ferritin below 100 µg/L, whereas subjects with a CRP below or equal to upper limit of normality must have a ferritin below 30 µg/L
- Willingness to participate after signing informed consent
Exclusion Criteria:
- Patient judged by the physician to be in need of surgery due to Crohn´s disease or ulcerative colitis within the next 2 months
- Anaemia predominantly caused by factors other than IDA
- Iron overload or disturbance in utilisation of iron (e.g. haemochromatosis and haemosiderosis)
- Known hypersensitivity to any excipients of iron isomaltoside 1000
- History of multiple allergies
- Decompensated liver cirrhosis and/or known chronic viral hepatitis (defined as Alanine Aminotransferase (ALAT) > 3 times upper limit of normal)
- Acute and/or chronic infections
- Body weight < 50 kg
- Rheumatoid arthritis with symptoms or signs of active joint inflammation
- Pregnancy and nursing. In order to avoid pregnancy, women have to be postmenopausal, surgically sterile, or use one of the following contraceptives during the whole study period and 5 days after the study has ended (i.e. 5 times plasma biological half-life of the investigational medicinal product): intrauterine devices and hormonal contraceptives (contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release)
- Blood transfusion within the previous 12 weeks
- Subjects with a history of asthma, allergic eczema, or other atopic allergy
- Planned elective surgery during the study
- Untreated Vitamin B12 or folate deficiency, defined as values below the lower reference range
- Participation in any other clinical study within 3 months prior to Screening
- IV iron treatment within 8 weeks prior to Screening
- Oral iron treatment within 1 week prior to Screening
- Erythropoiesis Stimulating Agent (ESA) treatment within 8 weeks prior to Screening
- Any other medical condition that, in the opinion of Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Group A Monofer
Depending on the body weight, subjects in Treatment Group A will receive a total dose of 1,500 mg or 2,000 mg IV iron isomaltoside 1000 where 1,500 mg is administered as a single infusion and 2,000 mg is divided into 2 administrations: 1 administration of 1,500 mg at baseline and 1 administration of 500 mg 1 week later.
All doses will be diluted in 100 ml normal saline (0.9 % sodium chloride) and administered by infusion over approximately 15 minutes.
|
1500-3000mg IV depending on HB level, sex and body weight
Other Names:
|
EXPERIMENTAL: Group B Monofer
Depending on the body weight, Subjects in Treatment Group B will receive a total dose of 2,500 mg or 3,000 mg IV iron isomaltoside 1000 divided into 2 administrations; 1 administration of 1,500 mg and 8 weeks later a second administration of 1,000 mg or 1,500 mg..
All doses will be diluted in 100 ml normal saline (0.9 % sodium chloride) and administered by infusion over approximately 15 minutes.
|
1500-3000mg IV depending on HB level, sex and body weight
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary objective of the study is to evaluate the safety of a high IV iron dosing regimen of iron isomaltoside 1000 in subjects with IDA secondary to IBD.
Time Frame: up to 16 weeks
|
type and incidence of adverse drug reactions (ADRs)
|
up to 16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the efficacy of a high IV iron dosing regimen of iron isomaltoside 1000
Time Frame: up to 16 weeks
|
obtain a target Hb (≥ 13 g/dL in men and ≥ 12g/dL in women)
|
up to 16 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2012
Primary Completion (ACTUAL)
December 1, 2014
Study Completion (ACTUAL)
December 1, 2014
Study Registration Dates
First Submitted
April 25, 2012
First Submitted That Met QC Criteria
May 15, 2012
First Posted (ESTIMATE)
May 16, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
April 29, 2015
Last Update Submitted That Met QC Criteria
April 28, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P-Monofer-IBD-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Bowel Disease
-
Centre Hospitalier Universitaire, AmiensFunding from DGOS (PHRC IR 2013 and PRME)CompletedPediatric Inflammatory Bowel DiseaseFrance
-
University of British ColumbiaCompletedInflammatory Bowel Disease 11Canada
-
University of ChicagoTerminatedInflammatory Bowel Disease (IBD)United States
-
University of Wisconsin, MadisonTerminatedInflammatory Bowel Disease (IBD)United States
-
Cedars-Sinai Medical CenterUnknownPediatric Inflammatory Bowel Disease
-
Hull University Teaching Hospitals NHS TrustWellcome/EPSRC Centre for Interventional and Surgical Sciences, University...RecruitingInflammatory Bowel Disease 1United Kingdom
-
Assiut UniversityNot yet recruitingIBD-Inflammatory Bowel Disease
-
University of Wisconsin, MadisonCompletedInflammatory Bowel Disease (IBD)United States
-
Kyungpook National University HospitalDaegu Catholic University Medical Center; Yeungnam University Hospital; DongGuk...RecruitingIdiopathic Chronic Inflammatory Bowel DiseaseKorea, Republic of
-
Assiut UniversityUnknownHepatobilliary Manifestations in Inflammatory Bowel Disease Patients
Clinical Trials on Iron Isomaltoside 1000
-
Pharmacosmos A/SCompleted
-
Seoul National University HospitalCompletedAnemia | Knee ArthropathyKorea, Republic of
-
Pharmacosmos A/SCompletedPatients With Chemotherapy Induced Anemia (CIA)United States
-
University of MalayaRecruitingAnemia | Post Partum HemorrhageMalaysia
-
Pharmacosmos A/SBioStataCompletedAnaemia in Chronic Kidney DiseaseSweden, United Kingdom
-
Pharmacosmos UK LtdBioStataCompletedIron Deficiency AnaemiaUnited Kingdom
-
Pharmacosmos A/SBioStataCompletedIron Deficiency AnemiaDenmark
-
Pharmacosmos A/SCompletedAnemia | Iron Metabolism Disorders | Deficiency Diseases | Anemia, Iron Deficiency | Hematologic DiseaseJapan
-
Pharmacosmos A/SCompleted
-
Ain Shams UniversityCompleted